Author Archives: Tom Weickert

Volunteer for schizophrenia clinical trial

Volunteer call out: Canakinumab adjunctive treatment to reduce symptoms and improve cognition in people with schizophrenia displaying elevated blood inflammatory markers What is the purpose of the study? You are invited to participate in a research study of a human immune cell-line antibody upon language, memory, and symptoms of schizophrenia. This human immune cell-line antibody, canakinumab, is a class of […]

Read more